Physician profile
Devendra G Wadwekar
NPI 1174504534
$38,875.17
in general payments reported to CMS, 2019-2025
66 companies · $4,551 in 2025
The $4,551 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,788 · 2021: $2,161 · 2022: $7,611 · 2023: $2,961 · 2024: $6,540 · 2025: $4,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,613 · Honoraria: $2,700 · Consulting Fee: $1,350 · Travel and Lodging: $1,140 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,125 · Gift: $59.40 · Education: $50.56 · Entertainment: $14.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,612.73 |
| Honoraria | $2,700.00 |
| Consulting Fee | $1,350.00 |
| Travel and Lodging | $1,139.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,125.00 |
| Gift | $59.40 |
| Education | $50.56 |
| Entertainment | $14.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,240.19 | 2019-2025 | Jardiance |
| Madrigal Pharmaceuticals | $6,952.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $6,013.48 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Mannkind Corporation | $5,812.65 | 2019-2025 | Afrezza |
| Insulet Corporation | $1,535.37 | 2019-2025 | Omnipod, Omnipod |
| Novo Nordisk INC | $1,069.06 | 2019-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $788.20 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $710.75 | 2019-2025 | |
| Medtronic, INC. | $629.64 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Medtronic Minimed, INC. | $558.01 | 2019-2020 | |
| Amgen INC. | $556.03 | 2019-2025 | Evenity, Prolia |
| Abbott Laboratories | $489.11 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Recordati_rare_diseases_inc. | $464.64 | 2021-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $455.43 | 2019-2025 | Synthroid |
| Radius Health, INC. | $452.15 | 2019-2025 | Tymlos |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $433.93 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $419.15 | 2020-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $418.40 | 2019-2025 | Farxiga, Lokelma |
| Antares Pharma, INC. | $397.29 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Novartis Pharmaceuticals Corporation | $332.91 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.93 | 2021-2025 | |
| Echosens North America, INC. | $274.41 | 2022-2023 | Fibroscan |
| Amneal Pharmaceuticals LLC | $177.83 | 2020-2025 | Unithroid |
| Cequr Corporation | $176.75 | 2023-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $156.27 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Alexion Pharmaceuticals, INC. | $137.38 | 2021-2023 | Strensiq |
| Eusa Pharma (US) LLC | $132.22 | 2022 | |
| Tandem Diabetes Care, INC. | $127.76 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar, INC. | $119.66 | 2024-2025 | Jatenzo |
| Verity Pharmaceuticals INC. | $99.14 | 2024-2025 | Tlando |
| Horizon Therapeutics Plc | $96.61 | 2019-2023 | Tepezza |
| Vivus LLC | $94.59 | 2019-2020 | |
| Amarin Pharma, INC. | $86.99 | 2019-2021 | |
| Astellas Pharma US INC | $77.12 | 2024-2025 | Veozah |
| Grt US Holding, INC. | $73.01 | 2021 | |
| Averitas Pharma INC. | $68.64 | 2023-2024 | Qutenza |
| Halozyme INC | $65.29 | 2023 | |
| Zealand Pharma US, INC. | $63.20 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $62.76 | 2019-2021 | |
| Clarus Therapeutics INC. | $62.45 | 2021 | |
| Ibsa Pharma INC. | $62.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.40 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $58.94 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $56.48 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $52.38 | 2022-2024 | Contrave |
| Ipsen Biopharmaceuticals, INC | $41.89 | 2019-2022 | |
| Amryt Pharma Holdings LTD | $40.96 | 2021-2023 | Mycapssa |
| Sequel Med Tech, LLC | $27.83 | 2025 | Twiist |
| Progenics Pharmaceuticals, INC. | $26.68 | 2022 | |
| Companion Medical, INC. | $24.50 | 2020 | |
| Vistapharm, INC. | $23.15 | 2021 | |
| Becton, Dickinson and Company | $19.09 | 2021 | |
| Gilead Sciences, INC. | $18.88 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.42 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $18.33 | 2024 | |
| Acerus Pharmaceuticals Corporation | $18.06 | 2022 | |
| Nevro Corp. | $16.52 | 2021 | |
| Embecta Corp. | $16.11 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Alvogen INC | $16.10 | 2023 | Teriparatide |
| Valeritas, INC. | $15.42 | 2019 | |
| Opko Pharmaceuticals, LLC | $15.35 | 2019 | |
| Boston Scientific Corporation | $14.95 | 2023 | |
| Optos, INC. | $14.44 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Roche Diabetes Care, INC. | $13.34 | 2019 | |
| Shire North American Group INC | $12.38 | 2019 | |
| Intuity Medical INC | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devendra Wadwekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.